Clinical Trials

Protocol The ROSETTA Lung-202 Trial (CA266-0002) is a Phase 3 study. It looks at how safe and effective a new treatment is for adults with advanced non-small cell lung cancer (NSCLC). This type of cancer has spread to nearby tissue or other parts of the body. The study compares the new treatment with the current standard-of-care (SOC), which is the treatment most commonly used by doctors. It is used as the first treatment for patients whose tumors have high levels of PD-L1, a protein that can stop the immune system from attacking cancer cells. The trial includes patients who cannot have surgery or chemoradiation.

We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced cervical cancer. The usual approach is defined as care most people get for advanced cervical cancer.

This study is testing 2 devices for blocked arteries. One is a new magnesium device that helps your artery heal and then slowly dissolves in about one year. Your body replaces it with natural materials. The other is a regular metal stent that stays in your body forever. Doctors want to learn which one is safer and works better.

SMT112-3005 HARMONi-GI3 The main goal of this study is to test the safety and benefits of the study drug Ivonescimab when it is given with drug called FOLFOX, a mix a platinum-based chemo drug used to treat certain cancers, most notably colorectal cancer. This treatment will be compared to another drug, Avastin, which is also given with FOLFOX, for people receiving their first treatment for cancer. This drug AK-112 is a new drug and has not been approved for use or sale by the U.S. Food and Drug Administration or local health authorities. Avastin is an approved drug.

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Want to learn more about the effectiveness and safety of the study drug rilvegostomig (also called AZD2936) compared to pembrolizumab, a standard treatment option for lung cancer. The study drug rilvegostomig may help your immune system (body defense) fight your cancer.

This study is to see if a special kind of pacemaker can help people with a certain type of heart problem called HFpEF. This means your heart pumps out blood normally, but it still doesn't work quite right. Some people in the study will get a pacemaker that is set to a heart rate based on their height and a number called LVEF. Others will get a pacemaker that does very little. LVEF is a number that shows how well your heart pumps blood. Doctors get this number from a test called an echocardiogram. This test uses sound waves to take pictures of your heart. The goal is to see if setting the pacemaker to a personalized heart rate helps people feel better.

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

(Closed at this site) This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.